GW Pharmaceuticals PLC (NASDAQ:GWPH) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Thursday.

According to Zacks, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. “

GWPH has been the subject of several other research reports. TheStreet raised GW Pharmaceuticals PLC from a “d+” rating to a “c-” rating in a research note on Tuesday, March 14th. Maxim Group started coverage on GW Pharmaceuticals PLC in a research note on Thursday, April 20th. They set a “buy” rating and a $135.00 price objective for the company. Cantor Fitzgerald reissued a “buy” rating and set a $208.00 price objective on shares of GW Pharmaceuticals PLC in a research note on Tuesday, May 9th. BidaskClub raised GW Pharmaceuticals PLC from a “strong sell” rating to a “sell” rating in a research note on Wednesday, June 14th. Finally, ValuEngine raised GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. GW Pharmaceuticals PLC currently has an average rating of “Buy” and a consensus price target of $160.16.

Shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) traded up 1.89% during mid-day trading on Thursday, hitting $102.08. The company had a trading volume of 194,532 shares. The company’s market capitalization is $2.58 billion. GW Pharmaceuticals PLC has a one year low of $79.62 and a one year high of $137.88. The company’s 50-day moving average is $101.55 and its 200 day moving average is $115.09.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last posted its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.50) by $0.20. The business had revenue of $2.04 million for the quarter, compared to the consensus estimate of $2.07 million. GW Pharmaceuticals PLC had a negative net margin of 1,021.38% and a negative return on equity of 22.81%. GW Pharmaceuticals PLC’s quarterly revenue was down 23.0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.06) EPS. On average, equities research analysts forecast that GW Pharmaceuticals PLC will post ($5.34) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Downgrades GW Pharmaceuticals PLC (GWPH) to Sell” was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2017/07/09/zacks-investment-research-downgrades-gw-pharmaceuticals-plc-gwph-to-sell.html.

Large investors have recently modified their holdings of the company. Envestnet Asset Management Inc. raised its stake in shares of GW Pharmaceuticals PLC by 23.7% in the fourth quarter. Envestnet Asset Management Inc. now owns 1,376 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 264 shares during the period. Blair William & Co. IL purchased a new stake in shares of GW Pharmaceuticals PLC during the first quarter valued at about $207,000. Nwam LLC purchased a new stake in shares of GW Pharmaceuticals PLC during the first quarter valued at about $208,000. Ladenburg Thalmann Financial Services Inc. raised its stake in shares of GW Pharmaceuticals PLC by 8.0% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,916 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 142 shares during the period. Finally, Tudor Investment Corp Et Al purchased a new stake in shares of GW Pharmaceuticals PLC during the fourth quarter valued at about $219,000. 75.65% of the stock is owned by hedge funds and other institutional investors.

About GW Pharmaceuticals PLC

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Get a free copy of the Zacks research report on GW Pharmaceuticals PLC (GWPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.